Pembrolizumab and Odetiglucan for Liver-Dominant Colorectal Cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a combination of two drugs, pembrolizumab and odetiglucan, in people whose colorectal cancer has spread mainly to the liver and has not responded to standard treatments. The goal is to see if this combination can shrink or slow the growth of liver tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have colorectal cancer that has spread mostly to the liver, with at least one measurable tumor in the liver.
- You should have already tried treatments including fluoropyrimidine, oxaliplatin, irinotecan, and a VEGF inhibitor (like bevacizumab). If your cancer has certain genetic features (KRAS/NRAS/BRAF wild-type), you also need to have tried an EGFR inhibitor (like cetuximab or panitumumab).
- Your tumor must be mismatch repair proficient (MMR-p) or not microsatellite instability-high (non-MSI-H).
- Any side effects from previous cancer treatments should have resolved to mild or no symptoms (grade 1 or better), except for stable hormone-related issues, mild neuropathy, or ongoing hair loss.
- You must be able to perform daily activities with little or no help (ECOG performance status 0, 1, or 2) and have a life expectancy of at least 3 months.
- You cannot have had prior treatment with a PD-1, PD-L1, or similar immunotherapy agent, or with odetiglucan, and must not have received chemotherapy, radiation, or other cancer therapy within 2 weeks before starting the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combinations of immunotherapy drugs for people with colorectal cancer that has spread to the liver and is scheduled for surgery. The goal is to see if these treatments are safe and effective before and after the operation.
This trial tests a combination of an immunotherapy drug (PD-1 inhibitor), growth factors, and chemotherapy (CapeOX) for people whose colorectal cancer has spread only to the liver. The goal is to see if this combination shrinks the tumors enough to allow surgery to remove them completely.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy and a targeted therapy (bevacizumab) to shrink liver metastases from colorectal cancer that cannot be surgically removed right now. The goal is to make the tumors small enough for surgery.
This study tests a combination of three drugs for patients with colorectal cancer that has spread to the liver. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests whether adding two targeted drugs (serplulimab and bevacizumab) to standard chemotherapy before surgery can improve outcomes for people with colorectal cancer that has spread to the liver. It is for those whose cancer has certain genetic features and is considered resectable.
This Phase 3 trial tests a treatment approach for colorectal cancer that cannot be removed with surgery at first but has spread only to the liver. It is intended for people whose tumor is RAS/BRAF “wild-type” and who are well enough to do daily activities, to see if the treatment can control the cancer better.
Hear when a new Colorectal Adenocarcinoma Metastatic in the Liver trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.